Eli Lilly to Invest $1 Bn in Hyderabad Contract Manufacturing & Oversight Facility

The US-based company will expand its manufacturing and global medicine supply capacity in Hyderabad, with the new plant and quality Center expected to generate significant employment opportunities.

Eli Lilly and Company on Monday announced plans to invest over $1 billion in India, focusing on new contract manufacturing and establishing a facility in Hyderabad to provide advanced technical capabilities and oversight for its contract manufacturing network across the country.

The Telangana Chief Minister’s Office (CMO) confirmed that the State has secured the $1 billion investment, marking one of the largest pharmaceutical investments in recent years.

The US-based company will expand its manufacturing and global medicine supply capacity in Hyderabad, with the new plant and quality Center expected to generate significant employment opportunities.

The company’s leadership met Telangana Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu at the Integrated Command Control Center to discuss the investment proposal, which reflects Eli Lilly’s growing interest in Telangana beyond its existing Global Capability Center (GCC).

“Lilly’s continued expansion in Hyderabad highlights the city’s emergence as a powerhouse in global healthcare innovation. Telangana means business. Hyderabad is a global city. Our government will support and welcome all industries looking to invest here,” said Chief Minister A. Revanth Reddy traces the city’s origins as a pharmaceutical hub to the establishment of IDPL during Prime Minister Indira Gandhi’s tenure.

Patrik Jonsson, executive vice president and president, Lilly International, Eli Lilly and Company, added, “We are making significant investments to increase manufacturing and medicine supply capacity around the world to help ensure patients have access to the medicines they need.”

The company noted that the investment aligns with the Make in India agenda. Since 2020, Eli Lilly has committed more than $55 billion to build, expand, and acquire facilities in the U.S. and globally, supporting growth from potential new medicines for diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune conditions.

The new Hyderabad facility, located in the city where the GCC opened in August, will serve as a hub offering advanced technical capabilities and oversight for Lilly’s contract manufacturing network across India. Recruitment for engineers, chemists, analytical scientists, quality control and assurance professionals, and management positions will commence immediately.

Industries and IT Minister D. Sridhar Babu said, “The company’s expansion in Hyderabad is a testament to Telangana’s dynamic industrial landscape and its growing influence in advanced healthcare manufacturing. The State’s focus on technology-driven infrastructure and ease of doing business continues to attract global leaders across sectors, and the life sciences sector in particular has been on accelerated growth.”

Stay tuned for more such updates on Digital Health News